文献速递泌尿生殖MR

基于MRI的前列腺特异性抗原密度可预测主动监测队列中的Gleason评分升级

MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort.
PubMed 文献 · AJR Am J Roentgenol · 2020-01-08

回顾性纳入166例经直肠超声引导活检诊断为Gleason 3+3、接受主动监测且至少有一次后续活检的男性,74例(44.6%)在后续活检中Gleason评分升级至7或更高。校正年龄和随访时间后,MRI前列腺特异性抗原密度与后续活检Gleason评分升级的比值比为1.9(95%CI 1.2-2.8,P=0.01)。

要点

  • PI-RADS 4-5分病灶中MRI PSAD≥0.15 ng/mL²者占51.93%,高于PI-RADS 1-3分病灶的22.22%(P=0.01)。
  • 升级组MRI PSAD中位数0.15 ng/mL²,未升级组0.11 ng/mL²(P=0.01)。
  • MRI PSAD与后续活检Gleason评分升级相关,校正后比值比1.9(95%CI 1.2-2.8)。

核心结论

  • MRI PSAD与初诊Gleason 3+3男性后续活检Gleason评分升级显著相关,作者认为该结果符合直觉但此前未见报道,并认为随着MRI使用增加,MRI PSAD可辅助主动监测男性的风险分层。

研究设计与样本

  • 回顾性研究,纳入166例经直肠超声引导活检诊断为Gleason 3+3、接受主动监测、已行MRI且至少有一次后续活检的男性。

关键影像表现/征象

  • PI-RADS 4-5分病灶中MRI PSAD≥0.15 ng/mL²者占51.93%,PI-RADS 1-3分病灶中占22.22%(P=0.01)。
  • 升级组MRI PSAD中位数0.15 ng/mL²,未升级组0.11 ng/mL²(P=0.01)。

诊断标准与关键数值

  • MRI PSAD以MRI测得前列腺体积与最接近MRI时间点的前列腺特异性抗原水平计算。
  • MRI PSAD与后续活检Gleason评分升级的比值比为1.9(95%CI 1.2-2.8,P=0.01),经年龄和随访时间校正。
  • 74例(44.6%)在后续活检中升级至Gleason评分7或更高。

临床应用与阅片要点

  • 对初诊Gleason 3+3并接受主动监测的男性,可结合MRI PSAD辅助风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. Elevated prostate-specific antigen density (PSAD) based on transrectal ultrasound (TRUS) measurements has been shown to be strongly associated with clinically significant disease and to predict progression on active surveillance (AS) for men with disease that is at a low stage or grade. We hypothesized that elevated MRI PSAD is similarly associated with increased risk of progression on subsequent biopsy. MATERIALS AND METHODS. In this retrospective study, men with Gleason score of 3+3 on diagnostic TRUS-guided biopsy who were managed with AS, had undergone MRI, and had at least one additional biopsy were included. MRI PSAD was calculated using prostate volume on MRI and prostate-specific antigen level temporally closest to the MRI. Multivariable logistics regression models were used to evaluate the association between MRI PSAD and predictors of upgrade on serial biopsy. RESULTS. A total of 166 patients were identified, of whom 74 (44.6%) were upgraded to a Gleason score of 7 or higher on subsequent biopsy. Lesions with Prostate Imaging Reporting and Data System (PI-RADS) scores of 4 and 5 more commonly had MRI PSAD of 0.15 ng/mL2 or higher (51.93% vs 22.22%, p = 0.01) than lesions with PI-RADS scores of 1-3. Median MRI PSAD was significantly higher in the upgraded group compared with the group that was not upgraded (0.15 ng/mL2 vs 0.11 ng/mL2, p = 0.01). MRI PSAD was significantly associated with increased odds of upgrading on subsequent biopsy (log transformation; odds ratio, 1.9 [95% CI, 1.2-2.8]; p = 0.01) after adjusting for age and length of follow-up. CONCLUSION. MRI PSAD was significantly associated with Gleason score upgrading on subsequent biopsy for men initially diagnosed with Gleason 3+3 disease. Although this result is intuitive, to our knowledge it has not been previously shown. As MRI utilization increases, MRI PSAD can aid in risk stratification for men managed with AS.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Washington SL, Baskin AS, Ameli N, et al. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. AJR Am J Roentgenol. 2020. PMID: 31913068. doi:10.2214/AJR.19.21559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。